ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Famotidine

Also written as “Atazanavir+Ritonavir+Tenofovir+Famotidine”, “Famotidine Tablets, 40 mg” and “Atazanavir/Ritonavir + Famotidine”.

Its studies are mostly in COVID-19 · HIV Infections · Ulcer · Arthritis, Juvenile · Heartburn, led by 8 companies.

Drug pageFamotidine: every studyMany companies study it; this page follows only the 13 they lead. All 52 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 7, 202113 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Leidos Life Sciences30 open or runningphase 2since Oct 7, 2021Oct 7, 2021none ahead
Amgenits history only20 open or runningphase 4since Mar 20, 2012Mar 19, 2007none ahead
Perrigoits history only20 open or runningphase 1since Dec 3, 2008Dec 3, 2008none ahead
Sun Pharmaceutical Industriesits history only20 open or runningno phasesince Feb 18, 2010Feb 18, 2010none ahead
Astellas Pharmaits history only10 open or runningphase 3since Sep 1, 2005Sep 1, 2005none ahead
Dr. Reddy's Laboratoriesits history only10 open or runningphase 1since Jan 12, 2012Jan 12, 2012none ahead
drpykessupplements.comits history only10 open or runningphase 4since Sep 21, 2020Sep 21, 2020none ahead
Pfizerits history only10 open or runningphase 1since Mar 24, 2014Mar 24, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Leidos Life Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2021First studies: 3 phase 2 studies in COVID-19First studyNCT05085574, NCT05077969, NCT05077332

TargetBeta

HRH2 →read by rule
“Histamine H2 receptor antagonist”ChEMBL 37, by rule

Studies

All 3 Leidos Life Sciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05085574COVID-192WithdrawnFeb 7, 20230
NCT05077969COVID-19 · United States2TerminatedJun 28, 20224
NCT05077332COVID-19 · United States2CompletedNov 10, 20254

How it is read

Names in the registry

  • “Famotidine”, 8 entries
  • “Atazanavir+Ritonavir+Tenofovir+Famotidine”, 4 entries
  • “Famotidine Tablets, 40 mg”, 2 entries
  • “Atazanavir/Ritonavir + Famotidine”, 2 entries
  • “Nirogacestat and Famotidine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.